

Saving babies lives care bundle version 3 (SBLCBv3) – What every sonographer should know

Ellen Dyer,
Lead Research Sonographer for POPs2
The Rosie Hospital, Cambridge




Saving babies lives care bundle version 3 (SBLCBv3) – What every sonographer wants to know

Ellen Dyer,

Lead Research Sonographer for POPs2

The Rosie Hospital, Cambridge



Your feedback from last year's ASM

“We want a dedicated session discussing the saving babies' lives care bundle!”

**MEET THE #BMUS2024
STREAM LEADS**

ELLEN DYER
OBSTETRICS

📅 12th December
📍 Plenary 1

- Saving Babies' Lives
- Renal conditions
- Working with research

I can't wait until December, see you at BMUS ASM?

BMUS

0:17 / 0:51

Overview



Background



Scene setting

Background to
SBLv3

Overview of the care
bundle elements
focusing on key
areas for
sonography



The questions to answer

Background to SBLCB



- In 2015 the Department of Health set a target to half the national still birth rate by 2025 to 3%
- MBRRACE (2015) Perinatal Confidential Enquiry identified failure to detect poor growth as a contributing factor to poor outcome
- Led to:
 - Saving Babies' Lives care bundle (2016)
 - Many departments adopting the GROW/ GAP protocol in a bid to improve their detection of poor growth

Updates to SBLCB

- SBLCBv2 (2019) –
 - Additional element to reduce the preterm birth rate
 - Introduction of uterine artery Doppler screening for element 2
- SBLCBv3 (2023) –
 - Addition of element 6 management of diabetes in pregnancy
 - Attempts to incorporate RCOG and NICE guidance

SBLCBv3: Aims to reduce perinatal mortality

1. Reducing smoking in pregnancy
2. Fetal growth: Risk assessment, surveillance and management
3. Raising awareness of reduced fetal movement
4. Effective fetal monitoring during labour
5. Reducing preterm births and optimizing perinatal care
6. Management of pre-existing diabetes in pregnancy

Trusts are required to submit data based upon KPIs from SBLCBv3 to the Clinical Negligence scheme for trust (CNST). Compliance means more money!


Element 2: Fetal Growth: Risk Assessment, Surveillance and Management

What is FGR?

“FGR is difficult to diagnose representing those fetuses that have failed to reach their growth potential.” SBLv3

Why is FGR important to identify?


- Associated increase chance of with fetal morbidity, stillbirth and neonatal death
- Element 2 identifies women most at risk of FGR caused by **placental insufficiency**
- FGR causes, however, are likely to be multi-factorial
- Enables enhanced monitoring, planning and timing of delivery to achieve the best outcome for baby



The risk factors listed here constitute those routinely assessed at booking, other risk factors exist and risk assessment must always be individualised taking into account previous medical and obstetric history and current pregnancy history. For women with maternal medical conditions and individuals with disease progression or institution of medical therapies may increase an individual's risk and necessitate monitoring with serial scanning. For women with a previous stillbirth, management must be tailored to the previous history i.e. evidence of placental dysfunction or maternal medical conditions. Serial measurement should be performed as per NICE antenatal care guideline.

[†]AC and/or EFW $< 10^{\text{th}}$ centile at the anomaly scan is a high risk factor. * Refer to risk assessment and identification section for advice on scan interval.

FGR and Aspirin



ASPREE (Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia trial)

What is the biology behind uterine artery screening?


Spiral arteries are “re-modelled” by trophoblastic invasion



In normal pregnancy they change from a tight coil to funnel like opening in placenta




Results in low resistance to flow upstream – in uterine artery




Uterine artery Doppler interpretation

Normal



PI **under** 95th centile normal

Abnormal



PI **over** 95th centile abnormal

Uterine artery Doppler chart

Ultrasound Obstet Gynecol 2008; 32: 128–132

Published online 6 May 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.5315

Reference ranges for uterine artery mean pulsatility index at 11–41 weeks of gestation

O. GÓMEZ, F. FIGUERAS, S. FERNÁNDEZ, M. BENNASAR, J. M. MARTÍNEZ, B. PUERTO and E. GRATACÓS

PI has to be very high to be abnormal, most women will not need an additional 28-week scan

Table 2 Reference intervals for mean uterine artery pulsatility index

GA (weeks)	5 th centile	50 th centile	95 th centile
11	1.18	1.79	2.70
12	1.11	1.68	2.53
13	1.05	1.58	2.38
14	0.99	1.49	2.24
15	0.94	1.41	2.11
16	0.89	1.33	1.99
17	0.85	1.27	1.88
18	0.81	1.20	1.79
19	0.78	1.15	1.70
20	0.74	1.10	1.61
21	0.71	1.05	1.54
22	0.69	1.00	1.47
23	0.66	0.96	1.41
24	0.64	0.93	1.35
25	0.62	0.89	1.30
26	0.60	0.86	1.25
27	0.58	0.84	1.21
28	0.56	0.81	1.17
29	0.55	0.79	1.13
30	0.54	0.77	1.10
31	0.52	0.75	1.06
32	0.51	0.73	1.04
33	0.50	0.71	1.01
34	0.50	0.70	0.99
35	0.49	0.69	0.97
36	0.48	0.68	0.95
37	0.48	0.67	0.94
38	0.47	0.66	0.92
39	0.47	0.65	0.91
40	0.47	0.65	0.90
41	0.47	0.65	0.89

Transvaginal and transabdominal ultrasound examinations were performed on pregnancies at 11–14 weeks and 15–41 weeks, respectively. GA, gestational age.

How does combining maternal factors and uterine artery Doppler improve the detection of PET/FGR?

Table II Comparison of predictive models in development and validation group in relation to ultrasound and maternal predictors of preeclampsia

	Both US and maternal		US alone		US vs both <i>P</i> =	Maternal alone		Maternal vs both <i>P</i> =	Maternal vs US <i>P</i> =
	Development Sample area under ROC curve	Validation sample	Development Sample area under ROC curve	Validation sample		Development sample area under ROC curve	Validation sample		
PET (all)	0.833	0.834	0.780	0.777	< .0001	0.721	0.719	< .0001	.006
PET < 34 wk	0.954	0.945	0.938	0.922	.27	0.798	0.741	< .0001	< .0001
PET ≥ 34 wk	0.800	0.798	0.736	0.729	< .0001	0.708	0.712	< .0001	.48

PET, preeclampsia.

Nearer the area under the curve is to 1, the better the test!

Yu CK, Smith GC, Papageorgiou AT, Cacho AM, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. *Am J Obstet Gynecol.* 2005 Aug;193(2):429-36. doi: 10.1016/j.ajog.2004.12.014. PMID: 16098866.er

Chart dilemmas

Which EFW chart should I use?

Currently no recommended chart for EFW by RCOG, ISUOG or SBLv3

BMUS third trimester guideline recommends Hadlock

Some argue IG21 or WHO charts better as they also have corresponding birthweight charts

Customised charts?

GROW/GAP from perinatal institute, lack of high-quality evidence

SBLCB neither recommends nor advises against customized charts – a decision for individual units



DESIGN study 2022: large RCT concluded GAP had no impact on the detection of SGA compared to standard care

Element 3 – Reduced fetal movements

- Recurrent RFM after 28 week are associated with an increased risk of still birth
- 1st episode RFM no scan required if cCTG normal
- Recurrent RFM after 28 week = growth scan
- No agreed definition of recurrent RFM

“two or more episodes of RFM occurring within a 21-day period after 26 weeks’ gestation”

- Induction of labour recommended prior to 39 for women with recurrent RFM and evidence of fetal compromise



Why are fetal movements important?


Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial

2018

Jane E Norman, Alexander E P Heazell, Aryelly Rodriguez, Christopher J Weir, Sarah J E Stock, Catherine J Calderwood, Sarah Cunningham Burley, J Frederik Frøen, Michael Geary, Fionnuala Breathnach, Alyson Hunter, Fionnuala M McAuliffe, Mary F Higgins, Edile Murdoch, Mary Ross-Davie, Janet Scott, Sonia Whyte, for the AFFIRM investigators

- Trialled the introduction of a care package to reduce still births
- All women with RFM after 26 weeks were scanned
- Small drop in the rate of stillbirth but not significant
- Did show reduction in small for gestational age babies born at term

Element 5 Reducing preterm birth



Short cervix: <25mm

Treatment: NICE progesterone, cerclage or Arabin pessary

SBLCBv3 - Element 5

Risk assessment	Risk factors	Screening/surveillance
High	<ul style="list-style-type: none">• Previous preterm birth or mid-trimester loss (16-34wks)• Previous preterm prelabour of membranes <34wks• Previous cervical cerclage• Known uterine variant• Intrauterine adhesions• H/O trachelectomy (for cervical cancer)	<ul style="list-style-type: none">• Refer to preterm birth prevention clinic (PTBPC) by 12weeks• TV cervical length every 2-4wks, between 16 and 24 weeks
Intermediate	<ul style="list-style-type: none">• Previous CS at full dilatation• H/O significant cervical excision event (>15mm)	<ul style="list-style-type: none">• Refer to PTBPC by 12wks• Single TV cervical length between 18-22wks

Why 25mm cut-off?





Figure 5 Risk for spontaneous delivery at ≤ 32 weeks according to cervical length at 23 weeks of gestation


Heath et al 1998

- 2567 women scanned at 23 weeks
- Below 15mm risk of spontaneous birth before 32 weeks 58%
- **At 25mm risk of spontaneous birth ~ 3%**


Cervical length and gestational age



- 6614 scans between 16 and 36 weeks for pregnancy
- Awareness of normal range useful to avoid over measurement
- Rationale of not measuring the cervix beyond 24 week





Easy?




Cervical length is key to accurate screening and management

- Cervical length remains the most effective way of screening
- Accuracy of measurements matters
- Practitioners need appropriate training
- Regular peer review is recommended



Conclusions



Sonographers have a key role to play in the successful delivery of the SBLCB



Understanding the rationale behind each SBLCB element is definitely useful

Questions for the morning.....

- Is the care bundle working? Is it preventing mortality and morbidity? How do we know?
- What can we do to tackle health inequalities amongst pregnant women?
- How can we better target interventions to distinguish between the “small and well” and the “small and struggling” baby?
- Where does the SBLCB sit within the wider maternity vision for improvements to care? Is it a priority?
- How can we all work together to improve pregnancy outcomes? Should sonographers be more involved in policy making?

Thank you for listening!



Stand 24



ellen.dyer@nhs.net